WAP
ZYME icon

Wealthcare Advisory Partners’s Zymeworks ZYME Stock Holding History

Wealthcare Advisory Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8
Closed – – 1315
2018
Q2 		$0 Hold
8
– – ﹤0.01% 1323
2018
Q1 		$0 Buy
+8
New +$87 ﹤0.01% 1263

Other funds holding ZYME

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Wealthcare Advisory Partners's ZYME Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Zymeworks (ZYME) in Q3 2018, closing a stake of 8 shares.

Wealthcare Advisory Partners first reported a position in ZYME in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 46 funds tracked by Wall St. Rank hold ZYME as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Zymeworks position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 8 Zymeworks shares in Q3 2018.
  • Wealthcare Advisory Partners first reported a position in Zymeworks in Q1 2018 and held it in 2 quarters.
  • Wealthcare Advisory Partners's Zymeworks position peaked at $0 in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Zymeworks as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.